Showing 4011-4020 of 5771 results for "".
- Luminopia One Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial for Amblyopiahttps://modernod.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/Luminopia announced the publication of positive phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One. Published in Ophthalmology, the study was conducted at 21 academic and community sites in the U.S., in which childre
- Outlook Therapeutics Presents Positive NORSE THREE Safety Data for Lytenava (bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-presents-positive-norse-three-safety-data-for-lytenava-bevacizumab-vikg-at-euretina/2479575/Outlook Therapeutics announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010/Lytenava (bevacizumab-vikg) at the EURETINA Virtual 2021 conference on September 12, 2021. The previously announced topline results from the open-label safety study demonstrated that
- AbbVie Makes Large Investment in Regenxbio's Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-eye-care-collaboration/2479577/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patient
- Clearside Biomedical Expands Xipere License Agreement with Arctic Visionhttps://modernod.com/news/clearside-biomedical-expands-xipere-license-agreement-with-arctic-vision/2479500/Clearside Biomedical announced it has agreed to expand the territories covered by its exclusive license agreement with China-based Arctic Vision. As now amended, the licensed territory for Xipere (triamcinolone acetonide suprachoroidal injectable suspension) has been expanded from
- Coburn Technologies Launches Waterless Lens Deblocking System and Alloy Recovery Systemhttps://modernod.com/news/coburn-technologies-launches-waterless-lens-deblocking-system-and-alloy-recovery-system/2479494/Coburn Technologies has officially launched the Reimagine Campaign to announce new technology advancements in lens processing. Coburn has developed a completely waterless lens deblocking system and a first-of-its-kind alloy recovery system for labs that use alloy for lens processing.
- Pixium Vision Expands Collaboration with Stanford University On Next Generation Prima System Implantshttps://modernod.com/news/pixium-vision-expands-collaboration-with-stanford-university-on-next-generation-prima-system-implants/2479492/Pixium Vision SA announced the expansion of a collaboration with academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD). “We are very excited to be extending our collaboration with
- Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congresshttps://modernod.com/news/oxurion-to-present-clinical-and-preclinical-data-at-upcoming-euretina-2021-virtual-congress/2479493/Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking p
- EyeGate Pharma Completes Target Enrollment in Phase 2 Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammationhttps://modernod.com/news/eyegate-pharma-completes-target-enrollment-in-phase-2-study-to-evaluate-pp-001-for-the-treatment-of-ocular-surface-inflammation/2479490/EyeGate Pharmaceuticals announced that it has completed target enrollment of 21 patients in the phase 2 proof-of-concept (POC) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001
- Horizon Therapeutics Initiates Phase 4 Clinical Trial Evaluating Tepezza for the Treatment of Chronic Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-initiates-phase-4-clinical-trial-evaluating-tepezza-for-the-treatment-of-chronic-thyroid-eye-disease/2479489/Horizon Therapeutics announced that the first patient has been enrolled in a phase 4 clinical trial evaluating the efficacy and safety of Tepezza for the treatment of chronic (inactive) Thyroid Eye Disease (TED). Tepezza is the first and only medicine approved by the FDA for the treatment of TED—
- Azura Ophthalmics Appoints Steven Altschuler, MD, as Chair of the Boardhttps://modernod.com/news/azura-ophthalmics-appoints-steven-altschuler-md-as-chair-of-the-board/2479486/Azura Ophthalmics announced the appointment of Steven M. Altschuler, MD, as chair of its board of directors. Dr. Altschuler brings more than 20 years of experience building, scaling, and leading health care and biotechnology companies. He currently serves as managing director of Healthcare Ventur